• Je něco špatně v tomto záznamu ?

Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet

I. Vaněčková, Z. Dobešová, J. Kuneš, Z. Vernerová, J. Zicha,

. 2015 ; 33 (1) : 161-9.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010735

BACKGROUND: Our previous experiments demonstrated that selective endothelin A (ETA) receptor blockade had antihypertensive effects in Ren-2 transgenic rats (TGRs), but the mechanisms responsible for this change of blood pressure (BP) have not been explored yet. METHOD: Four-week-old male heterozygous TGRs and their normotensive controls--Hannover Sprague-Dawley (HanSD) rats--were fed high-salt diet (2% NaCl) and were treated with selective ETA receptor blocker atrasentan (5 mg/kg per day) for 8 weeks. At the end of the study, the contribution of principle vasoactive systems was evaluated by the sequential blockade of the renin-angiotensin system (captopril), sympathetic nervous system (pentolinium) and nitric oxide synthase [N-nitro-L-arginine methyl ester (L-NAME)]. The role of calcium influx through L-type voltage-dependent calcium channels in BP maintenance was evaluated using nifedipine. In a separate group of animals, the efficiency of distinct vasodilator systems--prostanoids (blocked by nonselective cyclooxygenase inhibitor indomethacin) and Ca-activated K channels (inhibited by tetraethylammonium)--was also analyzed. RESULTS: Atrasentan attenuated the development of hypertension in heterozygous TGRs, but had no effects in Hannover Sprague-Dawley rats. Moreover, atrasentan moderately attenuated renin-angiotensin system-dependent vasoconstriction, whereas it had no effect on sympathetic vasoconstriction. The nifedipine-sensitive BP component was markedly decreased by atrasentan treatment. In contrast, vasodilatation mediated by nitric oxide, endogenous prostanoids or Ca-activated K channels was reduced in atrasentan-treated TGRs, indicating the absence of compensatory augmentation of endothelin B receptor-mediated vasodilation in these animals. CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010735
003      
CZ-PrNML
005      
20160414123624.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HJH.0000000000000357 $2 doi
024    7_
$a 10.1097/HJH.0000000000000357 $2 doi
035    __
$a (PubMed)25255392
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vaněčková, Ivana $u aInstitute of Physiology, Academy of Sciences of the Czech Republic bDepartment of Pathology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Endothelin A receptor blocker atrasentan lowers blood pressure by the reduction of nifedipine-sensitive calcium influx in Ren-2 transgenic rats fed a high-salt diet / $c I. Vaněčková, Z. Dobešová, J. Kuneš, Z. Vernerová, J. Zicha,
520    9_
$a BACKGROUND: Our previous experiments demonstrated that selective endothelin A (ETA) receptor blockade had antihypertensive effects in Ren-2 transgenic rats (TGRs), but the mechanisms responsible for this change of blood pressure (BP) have not been explored yet. METHOD: Four-week-old male heterozygous TGRs and their normotensive controls--Hannover Sprague-Dawley (HanSD) rats--were fed high-salt diet (2% NaCl) and were treated with selective ETA receptor blocker atrasentan (5 mg/kg per day) for 8 weeks. At the end of the study, the contribution of principle vasoactive systems was evaluated by the sequential blockade of the renin-angiotensin system (captopril), sympathetic nervous system (pentolinium) and nitric oxide synthase [N-nitro-L-arginine methyl ester (L-NAME)]. The role of calcium influx through L-type voltage-dependent calcium channels in BP maintenance was evaluated using nifedipine. In a separate group of animals, the efficiency of distinct vasodilator systems--prostanoids (blocked by nonselective cyclooxygenase inhibitor indomethacin) and Ca-activated K channels (inhibited by tetraethylammonium)--was also analyzed. RESULTS: Atrasentan attenuated the development of hypertension in heterozygous TGRs, but had no effects in Hannover Sprague-Dawley rats. Moreover, atrasentan moderately attenuated renin-angiotensin system-dependent vasoconstriction, whereas it had no effect on sympathetic vasoconstriction. The nifedipine-sensitive BP component was markedly decreased by atrasentan treatment. In contrast, vasodilatation mediated by nitric oxide, endogenous prostanoids or Ca-activated K channels was reduced in atrasentan-treated TGRs, indicating the absence of compensatory augmentation of endothelin B receptor-mediated vasodilation in these animals. CONCLUSION: BP-lowering effect of chronic atrasentan treatment in TGRs was mainly caused by reduced Ca influx through L-type voltage-dependent calcium channels due to missing ETA receptor-dependent vasoconstriction and attenuated angiotensin II-dependent vasoconstriction.
650    _2
$a krmivo pro zvířata $7 D000821
650    _2
$a zvířata $7 D000818
650    _2
$a antihypertenziva $x chemie $7 D000959
650    _2
$a krevní tlak $x fyziologie $7 D001794
650    _2
$a vápník $x chemie $x metabolismus $7 D002118
650    _2
$a vápníkové kanály - typ L $x metabolismus $7 D020746
650    _2
$a kaptopril $x chemie $7 D002216
650    _2
$a antagonisté endotelinového receptoru A $x chemie $7 D065130
650    _2
$a hypertenze $x patofyziologie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a NG-nitroargininmethylester $x chemie $7 D019331
650    _2
$a nifedipin $x chemie $7 D009543
650    _2
$a oxid dusnatý $x metabolismus $7 D009569
650    _2
$a synthasa oxidu dusnatého $x metabolismus $7 D019001
650    _2
$a pentoliniumtartrát $x chemie $7 D010425
650    _2
$a pyrrolidiny $x terapeutické užití $7 D011759
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a potkani transgenní $7 D055647
650    _2
$a renin $x genetika $7 D012083
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
650    _2
$a kuchyňská sůl $x farmakologie $7 D017673
650    _2
$a sympatický nervový systém $x patofyziologie $7 D013564
650    _2
$a vazokonstrikce $x účinky léků $7 D014661
650    _2
$a vazodilatace $x účinky léků $7 D014664
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dobešová, Zdenka
700    1_
$a Kuneš, Jaroslav
700    1_
$a Vernerová, Zdenka
700    1_
$a Zicha, Josef
773    0_
$w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 33, č. 1 (2015), s. 161-9
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25255392 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20160414123708 $b ABA008
999    __
$a ok $b bmc $g 1114164 $s 935103
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 33 $c 1 $d 161-9 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...